Gland Pharma Limited has announced the approval of a grant of 16,790 employee stock options under its ESOP 2025 scheme. This decision was made by the ESOP Compensation Committee of the Board of Directors on July 30, 2026. The options are being granted to three employees of the company, with a pricing structure that includes a portion at 50% of the closing price and another at face value.
Stock Option Grant Approved
Gland Pharma Limited has officially approved the grant of 16,790 Employee Stock Options as part of its Gland Pharma Employee Stock Option Scheme, 2025 (“ESOP 2025”). This significant decision was finalized by the ESOP Compensation Committee of the Board of Directors during a meeting held on July 30, 2026. The grant is intended for 03 employees of the company.
Details of the Grant
The total number of shares covered by these options amounts to 16,790. The pricing formula for these options is structured in two parts: 11,081 options are priced at INR 1258.50 each, representing 50% of the equity share’s closing price on the NSE on the grant date. The remaining 5,709 options are priced at INR 1/-, which is the face value of the equity share.
Vesting Schedule and Exercise Period
The stock options are subject to a phased vesting schedule. 34% of the granted options will vest upon completion of the first year from the vesting date, i.e., July 30, 2027. Subsequently, 33% will vest upon completion of the second year (July 30, 2028), and the final 33% will vest upon completion of the third year (July 30, 2029). Employees will have a maximum period of two years from the date of vesting within which to exercise their options.
Source: BSE
